Ausgabe 4/2014
Inhalt (7 Artikel)
Practical Guidelines for Therapeutic Drug Monitoring of Anticancer Tyrosine Kinase Inhibitors: Focus on the Pharmacokinetic Targets
Huixin Yu, Neeltje Steeghs, Cynthia M. Nijenhuis, Jan H. M. Schellens, Jos H. Beijnen, Alwin D. R. Huitema
Pooled Population Pharmacokinetic Analysis of Phase I, II and III Studies of Linifanib in Cancer Patients
Ahmed Hamed Salem, Denise Koenig, Dawn Carlson
Integrated Population Pharmacokinetic/Viral Dynamic Modelling of Lopinavir/Ritonavir in HIV-1 Treatment-Naïve Patients
Kun Wang, David Z. D’Argenio, Edward P. Acosta, Anandi N. Sheth, Cecile Delille, Jeffrey L. Lennox, Corenna Kerstner-Wood, Ighovwerha Ofotokun
Influence of Gestational Age and Body Weight on the Pharmacokinetics of Labetalol in Pregnancy
James H. Fischer, Gloria E. Sarto, Jennifer Hardman, Loraine Endres, Thomas M. Jenkins, Sarah J. Kilpatrick, Hyunyoung Jeong, Stacie Geller, Kelly Deyo, Patricia A. Fischer, Keith A. Rodvold
Randomised, Double-Blind, Placebo-Controlled, Dose-Escalating Phase I Study of QGC001, a Centrally Acting Aminopeptidase A Inhibitor Prodrug
Fabrice Balavoine, Michel Azizi, Damien Bergerot, Nadia De Mota, Rémi Patouret, Bernard P. Roques, Catherine Llorens-Cortes